Patent intelligence · EP
EP 1655027
Verwendung von 9-(N-methyl-piperidyliden-4)-thioxanthene zur Behandlung von pulmoler Hypertension und Migräne
Verwendung von 9-(N-methyl-piperidyliden-4)-thioxanthene zur Behandlung von pulmoler Hypertension und Migräne
Patent details — EP 1655027
- Jurisdiction
- EP
- Status
- expired
- Grant date
- May 10, 2006
- Expiration
- May 5, 2026
- Applicant
- BIOFRONTERA PHARMACEUTICALS GM [DE]
- CPC classes
- A61K 31/ 4535 A I, A61K/314535, A61P 1/ 00 A I, A61P 9/ 00 A I
Quick answer
EP 1655027 (Verwendung von 9-(N-methyl-piperidyliden-4)-thioxanthene zur Behandlung von pulmoler Hypertension und Migräne) is held by BIOFRONTERA PHARMACEUTICALS GM [DE]. Status: expired. Granted May 10, 2006. Expires May 5, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOFRONTERA PHARMACEUTICALS GM [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4535 A I, A61K/314535, A61P 1/ 00 A I, A61P 9/ 00 A I, A61P 9/ 08 A I, A61P 15/ 00 A I
More from BIOFRONTERA PHARMACEUTICALS GM [DE]
Related pharmaceutical patents in our USPTO index.
-
US 20260108463
NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION
granted -
US 2024335360
PRESSURIZED NANOEMULSION
granted -
WO 2024209065
NANOÉMULSION SOUS PRESSION
granted -
WO 2024209064
NANOÉMULSION SANS PROPYLÈNE GLYCOL
granted -
US 2024335380
NANOEMULSION WITHOUT PROPYLENE GLYCOL
granted -
US 2021315993
PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS
granted -
WO 2014117863
FORMES POLYMORPHES DE SELS D'ADDITION D'ACIDE DE THIOXANTHÈNE-9-YLIDÈNE-1-MÉTHYLPIPÉRIDINES UTILISÉS COMME COMPOSÉS ANTIMIGRAINEUX
granted -
DE 202010004750
Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
granted
Frequently asked questions
What is US patent 1655027?
EP 1655027 (Verwendung von 9-(N-methyl-piperidyliden-4)-thioxanthene zur Behandlung von pulmoler Hypertension und Migräne) is held by BIOFRONTERA PHARMACEUTICALS GM [DE]. Status: expired. Granted May 10, 2006. Expires May 5, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1655027?
BIOFRONTERA PHARMACEUTICALS GM [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does EP 1655027 expire?
Our index shows an expiration date of May 5, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.